×

Enrolling: Bateman-Horne InTime Drug Intervention Trial

  • September 28, 2018
  • By
The InTime Trial aims to assess the effects of the investigational drug, CT38, in terms of its safety and effectiveness in treating ME/CFS. There will be 18 people between 18 and 60 years of age enrolled in this study and participation will last up to approximately 4 months.
Who:
Dr. Lucinda Bateman, Located in Salt Lake City, Utah at the Bateman-Horne Institute.

When:

Ongoing


What:

A Clinical Trial for ME/CFS Patients: BHC is conducting a small interventional trial, to test the effectiveness of a new drug that may improve functioning and/or reduce the symptoms in ME/CFS patients. The drug has been shown to be safe in a Phase 1 trial in healthy humans.


Where:

Bateman-Horne Institute, Salt Lake City, Utah


How to Participate:

If you are interested in participating in this trial, please follow the link below and fill out the following form to check for eligibility:

https://redcap01.brisc.utah.edu/ccts/redcap/surveys/?s=MC4EAT4YNE

Categories: Enrolling studies, Research, Science, Utah

Support our work!

Did you find this content useful?
Help us keep going and keep growing. Make a recurring donation today.

Most people don't take the time to donate but if every visitor pledged just $2 per month on a recurring basis, we could fully fund #MEAction.
Donate

Leave a Reply

Your email address will not be published. Required fields are marked *